Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.
Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Ling Huang Z, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg AE, Garon EB, Liu B, Dubinett SM. Salehi-Rad R, et al. Among authors: lim rj. J Immunother Cancer. 2023 Sep;11(9):e006896. doi: 10.1136/jitc-2023-006896. J Immunother Cancer. 2023. PMID: 37730274 Free PMC article.
Multi-organ landscape of therapy-resistant melanoma.
Liu S, Dharanipragada P, Lomeli SH, Wang Y, Zhang X, Yang Z, Lim RJ, Dumitras C, Scumpia PO, Dubinett SM, Moriceau G, Johnson DB, Moschos SJ, Lo RS. Liu S, et al. Among authors: lim rj. Nat Med. 2023 May;29(5):1123-1134. doi: 10.1038/s41591-023-02304-9. Epub 2023 Apr 27. Nat Med. 2023. PMID: 37106167 Free PMC article.
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Among authors: lim rj. Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13. Nat Med. 2010. PMID: 20072130 Free PMC article.
Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial.
Lim RJ, Qiu X, Leong RN, Gutierrez JL, Halima A, Mostafa M, Ghoneim Y, Abdrabo M, Rashad M, Hannawi S, Liu Y, Mojares Z. Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):315-328. doi: 10.7774/cevr.2024.13.4.315. Epub 2024 Oct 31. Clin Exp Vaccine Res. 2024. PMID: 39525677 Free PMC article.
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.
Lim RJ, Qiu X, Alberto E, Capeding MR, Carlos J, Leong RN, Gutierrez JL, Trillana M, Liu Y, Mojares Z. Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):329-337. doi: 10.7774/cevr.2024.13.4.329. Epub 2024 Oct 31. Clin Exp Vaccine Res. 2024. PMID: 39525672 Free PMC article.
All-electrical skyrmionic magnetic tunnel junction.
Chen S, Lourembam J, Ho P, Toh AKJ, Huang J, Chen X, Tan HK, Yap SLK, Lim RJJ, Tan HR, Suraj TS, Sim MI, Toh YT, Lim I, Lim NCB, Zhou J, Chung HJ, Lim ST, Soumyanarayanan A. Chen S, et al. Among authors: lim rjj. Nature. 2024 Mar;627(8004):522-527. doi: 10.1038/s41586-024-07131-7. Epub 2024 Mar 20. Nature. 2024. PMID: 38509277
25 results